In a recent paper, Solomon et al. described for the first time G810 R/S/C RET solvent front resistance mutations analyzing ctDNA from two RET+ advanced NSCLC patients progressing on selpercatinib; these findings were further confirmed via postmortem biopsies [66,67,68]. This evidence concerns the gene RET and non-small cell lung carcinoma.